about
Insights into Bacteriophage Application in Controlling Vibrio SpeciesBacteriophage remediation of bacterial pathogens in aquaculture: a review of the technologyBacteriophages and phage-derived proteins--application approachesBacteriophage-resistant mutants in Yersinia pestis: identification of phage receptors and attenuation for miceNew Insights into Pathogenic Vibrios Affecting Bivalves in Hatcheries: Present and Future Prospects.Bacteriophage therapy of a Vibrio parahaemolyticus infection caused by a multiple-antibiotic-resistant O3:K6 pandemic clinical strain.phiSITE: database of gene regulation in bacteriophagesClassification of 17 newly isolated virulent bacteriophages of Pseudomonas aeruginosa.Phenotypic and genotypic variations within a single bacteriophage species.PHACTS, a computational approach to classifying the lifestyle of phagesPhage treatment of human infections.In vivo characteristics of targeted drug-carrying filamentous bacteriophage nanomedicinesIsolation and Comparative Genomic Analysis of T1-Like Shigella Bacteriophage pSf-2.Application of peptide displaying phage as a novel diagnostic probe for human lung adenocarcinoma.Propionibacterium acnes bacteriophages display limited genetic diversity and broad killing activity against bacterial skin isolates.Phage therapy treatment of the coral pathogen Vibrio coralliilyticus.Learning from bacteriophages - advantages and limitations of phage and phage-encoded protein applications.Bacteriophage application to control the contaminated water with Shigella.Alternative approaches to conventional treatment of acute uncomplicated urinary tract infection in women.Phage therapy and photodynamic therapy: low environmental impact approaches to inactivate microorganisms in fish farming plants.Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy.Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine.The post-antibiotic era: promising developments in the therapy of infectious diseases.Challenges and future prospects of antibiotic therapy: from peptides to phages utilization.Phage therapy: eco-physiological pharmacology.Bacteriophages safely reduce Salmonella contamination in pet food and raw pet food ingredientsAntibacterial efficacy of lytic Pseudomonas bacteriophage in normal and neutropenic mice models.Isolation of a novel bacteriophage specific for the periodontal pathogen Fusobacterium nucleatum.Pro- and anti-inflammatory responses of peripheral blood mononuclear cells induced by Staphylococcus aureus and Pseudomonas aeruginosa phages.[Beyond antibiotic therapy - Future antiinfective strategies - Update 2017].Bacterial competition and quorum-sensing signalling shape the eco-evolutionary outcomes of model in vitro phage therapyPhages in modified alginate beads.Unexploited opportunities for phage therapy.Genome sequencing and analysis of an Escherichia coli phage vB_EcoM-ep3 with a novel lysin, Lysep3.Two-stage, self-cycling process for the production of bacteriophages.Bacteriophage therapy to combat bacterial infections in poultry.Microencapsulation of Clostridium difficile specific bacteriophages using microfluidic glass capillary devices for colon delivery using pH triggered release.Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in wax moth larvae.Co-evolutionary dynamics of the bacteria Vibrio sp. CV1 and phages V1G, V1P1, and V1P2: implications for phage therapy.Priming innate immune responses to infection by cyclooxygenase inhibition kills antibiotic-susceptible and -resistant bacteria.
P2860
Q26739744-B1D5A5AB-3CE9-43ED-8196-358DEE4701FBQ26998710-A6990D42-C5E0-4383-A5A6-24484A068DCEQ28082731-EDDC1192-3123-43F0-B213-D8B8CEB7F8B0Q28477274-2FFC2828-67F4-4EB1-A47C-015AA636303FQ30234427-8890A6DE-3482-4BB6-A3F2-C3C91C84706FQ30359301-466A8AA9-E802-48D6-9EEE-420E52C0CBC7Q33600729-2AB86FF6-86AE-4D87-A053-C75ED8DDA991Q33746414-7F16DCC3-CFE9-4E06-B57A-AE1E5324FE0AQ33853311-3D46BE0D-F039-4450-965B-4644888AFE7AQ34124824-2903D3F8-B9B1-4CA8-87AC-16708756268EQ34254407-5C6D2B23-0B6A-4400-B90B-44EE0C639CDBQ35763456-FDF1E22C-CD2A-4DD4-B2D7-815BF6DC84C7Q35854136-86A3CB2D-3D7A-41CB-9969-C45C7AA19B4AQ35892258-C0A3F9A1-635B-44BE-BDAE-CA60759E6F10Q36250598-A1FE5832-4213-4E50-8F96-9AC55CDDD3C2Q36644509-BA191809-8994-4791-A4A6-4E3E91F6B86FQ36676044-362491DA-461F-4BA1-B0C4-9EB5FA2A6AEFQ36682033-A995BCF8-347C-433A-AC35-35E90C8D3AFAQ36754301-40D2EDE0-9785-4801-A355-B4B073DC6809Q37389925-DB703FD5-A6BC-4424-9B59-EED45DE318A9Q37928694-24808239-2311-46E0-9B1E-421E3EF8AE03Q38004869-54FD2430-B643-48F1-B34B-AEAE8190570CQ38106970-F5F90585-751A-45E1-8E65-FC7A30415B0EQ38214603-E8A8B99E-8B50-4B5D-BDEF-DE038703129EQ38230407-0B12E590-94A0-4AB4-A776-80CA63074D55Q39293584-C2DBE407-3943-406E-9283-A80838735674Q39671563-275B23DD-C8E1-4676-AD01-C84511F73DDCQ39836282-DEEA924B-A12D-48FA-B2C2-9C94B9B38441Q40093280-B47827D4-8AEA-4E0C-BDEF-511BAC4DD150Q40161010-0C8B4818-62B4-4FB6-8980-B644498C45CBQ40356497-9F1528C5-CA46-4C2A-A797-C0DB38B855E3Q40831458-A6EDB92D-F0F1-4FA1-A8CA-DEF8848ECDC6Q40964122-C1C9DEBA-3532-48DF-899D-164A73EB6A03Q41115248-B828E4D5-E0FD-4DF6-8EAB-B34233A5597AQ41671442-FCAC9ECB-F84C-4812-9671-FEE761F14FCDQ41718786-C7B528F1-E06D-4FB5-AC8A-F7818FE446BBQ41918244-2970DA6D-DBCA-4677-9D00-37901ABAE42AQ42012908-9ADAD480-ED28-4DC3-B78A-601CF163A978Q42271486-FD71EA1D-D98B-4E31-A334-6068BF24DF40Q42314739-83131A00-027D-47D2-ACF2-3D2E30634C55
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phage therapy.
@en
Phage therapy.
@nl
type
label
Phage therapy.
@en
Phage therapy.
@nl
prefLabel
Phage therapy.
@en
Phage therapy.
@nl
P1433
P1476
Phage therapy.
@en
P2093
John N Housby
Nicholas H Mann
P304
P356
10.1016/J.DRUDIS.2009.03.006
P577
2009-03-11T00:00:00Z